XASX
HXL
Market cap1mUSD
Oct 24, Last price
0.01AUD
Name
Hexima Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.73%
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-934k
L-51.33%
CFO
-162k
L-90.82%
Profile
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | 1,485 -74.45% | ||||||||
Cost of revenue | 557 | 3,284 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (557) | (1,800) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (62) | (1,177) | |||||||
Tax Rate | |||||||||
NOPAT | (496) | (622) | |||||||
Net income | (934) -51.33% | (1,919) -80.85% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (4) | ||||||||
BB yield | 0.10% | ||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (2,226) | (2,189) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (162) | (1,763) | |||||||
CAPEX | |||||||||
Cash from investing activities | 98 | 39 | |||||||
Cash from financing activities | 100 | (4) | |||||||
FCF | 97 | 581 | |||||||
| Balance | |||||||||
Cash | 2,226 | 2,189 | |||||||
Long term investments | |||||||||
Excess cash | 2,226 | 2,115 | |||||||
Stockholders' equity | 2,020 | 2,782 | |||||||
Invested Capital | 667 | ||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 167,040 | 167,040 | |||||||
Price | 0.01 -47.62% | 0.02 -30.00% | |||||||
Market cap | 1,837 -47.62% | 3,508 -23.42% | |||||||
EV | (389) | 1,318 | |||||||
EBITDA | (557) | (1,788) | |||||||
EV/EBITDA | 0.70 | ||||||||
Interest | 33 | ||||||||
Interest/NOPBT | |||||||||